Antimyosin antibody imaging in experimental aortic regurgitation.
BACKGROUND
Fiber dropout and myocyte necrosis precede heart failure in experimental aortic regurgitation (AR). The current study aimed to determine whether this process can be detected by noninvasive scintigraphic imaging.


RESULTS
111In-labeled antimyosin antibody Fab fragment (1 to 1.5 mCi) (Myoscint) was administered to each of 34 New Zealand White rabbits: 11 early (3 to 5 weeks) after surgical AR induction; 9 late (98 to 128 weeks) after AR induction; 5 normal and 3 sham-operated age-matched with early AR; and 3 normal and 3 sham-operated age-matched with late AR. Echocardiographic fractional shortening was indistinguishable among control, early AR, and late AR groups. In vivo gamma camera imaging 24 and 48 hours after isotope administration, post-mortem heart activity determination (percentage injected dose per gram), and autoradiography were performed. At 24 and 48 hours, heart-to-lung counts-per-pixel ratios from in vivo images were greater (p < 0.05) in the late AR rabbits than in each of the three other groups. No significant differences were found when early AR and older or younger control rabbits were compared. Heart activity (percentage injected dose per gram) in late AR rabbits trended toward higher values than in age-matched control rabbits (p = 0.057), but in early AR it was indistinguishable from that in the corresponding control (p = 0.413, difference not significant). The autoradiographic endocardial/epicardial activity ratio in late AR rabbits was greater than in control and early AR rabbits (1.27 +/- 0.13 vs 1.06 +/- 0.09 and vs 1.13 +/- 0.10, respectively, p < 0.02).


CONCLUSIONS
Whereas isotope uptake in late AR rabbits differed from that in control and early AR rabbits, systolic function was indistinguishable. Thus 111In-labeled antimyosin antibody imaging may permit noninvasive detection of AR-induced myocardial damage before functional deterioration.
Lu
P
P
Division of Cardiology, Cornell University Medical College, New York Hospital-Cornell Medical Center, New York, N.Y. 10021, USA.
Zanzonico
P
P
Goldfine
S M
SM
Hardoff
R
R
Magid
N
N
Gentile
R
R
Herrold
E M
EM
Borer
J S
JS
D000818:Animals; D000911:Antibodies, Monoclonal; D001022:Aortic Valve Insufficiency / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D001345:Autoradiography; D002303:Cardiac Output, Low / Q000473:pathology; D016022:Case-Control Studies; D015150:Echocardiography, Doppler; D004699:Endocardium / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D005500:Follow-Up Studies; D006321:Heart / Q000000981:diagnostic imaging; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008168:Lung / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D018485:Muscle Fibers, Skeletal / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009218:Myosins / Q000493:pharmacokinetics; D009336:Necrosis; D009942:Organometallic Compounds; D010496:Pericardium / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013599:Systole
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C058899:imciromab pentetate; D009218:Myosins